Inflazome announces the appointment of three leading experts in regulatory affairs, product development and biology to its Management Team.
Inflazome opens a new office in Cambridge, UK to accommodate employees in the centre of the UK’s pharmaceutical industry
Inflazome announces the appointment of two industry leaders with extensive drug discovery and development expertise to its Management Team
Inflazome raises $17m from Novartis Venture Fund and Fountain Healthcare Partners to develop treatments for chronic inflammatory diseases.
The New Yorker's Jerome Groopman writes about new discoveries around inflammation.
Dr. Matt Cooper, Inflazome's CEO, interviewed about new scientific discoveries regarding inflammation.
Read about Prof. Luke O'Neill's promising research to stop inflammation.